Information Provided By:
Fly News Breaks for September 17, 2019
ALDR
Sep 17, 2019 | 07:14 EDT
Credit Suisse analyst Evan Seigerman raised his price target for Alder Biopharmaceuticals to $19 from $11 to reflect the agreement reached for Lundbeck to acquire Alder. The analyst continues to believe that eptinezumab is likely to be approved by the EMA by 2021, entitling shareholders to receive $2/share in connection with the CVR. He reiterates a Neutral rating on the shares.
News For ALDR From the Last 2 Days
There are no results for your query ALDR